Explore Research companies and service providers in the pharmaceutical sector
The human immune system is a complex network of cells, tissues, and signaling molecules that serves as a defense system. It continuously identifies and eliminates viruses,…
The approval of amyloid-targeting monoclonal antibodies by the MHRA marked a clear regulatory and scientific milestone in Alzheimer’s disease treatment. These agents demonstrated…
Public attention to nicotinamide mononucleotide has grown quickly as evidence about NAD+ biology has entered mainstream discussion. Early animal data suggested broad benefits…
For patients living with blood cancer or a severe blood disorder, a stem cell transplant is often the turning point between decline and recovery. Yet for years in the UK, the…
Chronic illness drives demand across the NHS and shapes budgets, workforce planning and service design. People living with multiple long-term conditions account for around half of…
Calciphylaxis, also termed calcific uremic arteriolopathy, is uncommon yet catastrophic. Small and medium dermal arterioles mineralise and thrombose, tissue perfusion collapses,…
Cellular ageing is not a single event but a convergence of gradual molecular failures that accumulate over time. The recognised hallmarks include telomere attrition, genomic…
Gene therapy is moving from specialist promise to established practice in 2025. Approvals have broadened across indications, clinical data in Huntington's disease have shifted…
Human gene editing sits at a pivotal point in modern medicine. Its capacity to change DNA with precision has moved from conjecture to clinical practice, raising hopes for curative…
Huntington's disease remains without a cure in 2025. Clinical practice focuses on symptom control while a new wave of molecular programmes seeks to slow or halt neurodegeneration.…
For acute pain, time matters. Patients with postoperative dental pain, primary dysmenorrhoea, tension-type headache or migraine want relief that begins quickly and remains…
Liquid biopsies NHS pilot tests multi-cancer early detection to reshape screening pathways and achieve 75% Stage I-II cancer diagnosis by 2028.
Stay Updated on Research
Get the latest industry news and company updates delivered to your inbox
We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy